ACE2, Metformin, and COVID-19

Overview

Journal iScience

Publisher Cell Press

Date 2020 Aug 21

PMID 32818905

Citations 34

Authors

Atul Malhotra

Mark Hepokoski

Karen C McCowen

John Y-J Shyy

Affiliations

Soon will be listed here.

Abstract

COVID-19 is becoming a leading cause of mortality throughout the world, and few effective therapies are currently available. Angiotensin converting enzyme 2 (ACE2) is essential to COVID-19 pathogenesis, as the binding of SARS-CoV-2 spike protein (S protein) is required for viral entry and development of COVID-19. ACE2 regulates the protective arm of the renin-angiotensin-aldosterone system (RAAS) that endows anti-hypertensive and anti-inflammatory effects in the cardiovascular and pulmonary systems. Preclinical data suggest ACE2 might be downregulated after SARS-CoV-2 binding, and treatments that increase ACE2 may prevent cardiopulmonary injury. Development, testing, and mass production of novel ACE2 therapies may take years, whereas more effective treatments for COVID-19 are needed urgently. Metformin is a widely available anti-diabetic agent that has an excellent safety profile, and clinical and preclinical data suggest metformin may offer cardiopulmonary protection in COVID-19 via enhanced ACE2 expression.

Citing Articles

Does the Consumption of Metformin Correlate With a Reduction in Mortality Among Patients With Type 2 Diabetes and COVID-19 in Morocco?.

Benfathallah B, Cherkani Hassani A, El Hilali S, Abouqal R, Benchekroun L Cureus. 2025; 17(1):e77288.

PMID: 39931619 PMC: 11809767. DOI: 10.7759/cureus.77288.

Novel insights into the central protective role of ACE2 in diabetic cardiomyopathy: from underlying signaling pathways to therapeutic perspectives.

Li X, Qu S Mol Cell Biochem. 2025; .

PMID: 39928210 DOI: 10.1007/s11010-024-05196-6.

Metformin in Antiviral Therapy: Evidence and Perspectives.

Halabitska I, Petakh P, Lushchak O, Kamyshna I, Oksenych V, Kamyshnyi O Viruses. 2025; 16(12.

PMID: 39772244 PMC: 11680154. DOI: 10.3390/v16121938.

Human microbiome in post-acute COVID-19 syndrome (PACS).

Fallah A, Sedighian H, Kachuei R, Fooladi A Curr Res Microb Sci. 2024; 8:100324.

PMID: 39717208 PMC: 11665312. DOI: 10.1016/j.crmicr.2024.100324.

Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action.

Liang Y, Quan X, Gu R, Meng Z, Gan H, Wu Z Heliyon. 2024; 10(16):e35988.

PMID: 39247343 PMC: 11379597. DOI: 10.1016/j.heliyon.2024.e35988.

References

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Chen X, Walther F, Sengers R, Laghmani E, Salam A, Folkerts G . Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response. Am J Physiol Lung Cell Mol Physiol. 2015; 309(3):L262-70. PMC: 4525117. DOI: 10.1152/ajplung.00389.2014. View

Santos R, Sampaio W, Alzamora A, Motta-Santos D, Alenina N, Bader M . The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018; 98(1):505-553. PMC: 7203574. DOI: 10.1152/physrev.00023.2016. View

Tsaknis G, Siempos I, Kopterides P, Maniatis N, Magkou C, Kardara M . Metformin attenuates ventilator-induced lung injury. Crit Care. 2012; 16(4):R134. PMC: 3580719. DOI: 10.1186/cc11439. View

Ouyang J, Isnard S, Lin J, Fombuena B, Marette A, Routy B . Metformin effect on gut microbiota: insights for HIV-related inflammation. AIDS Res Ther. 2020; 17(1):10. PMC: 7063824. DOI: 10.1186/s12981-020-00267-2. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Luo P, Qiu L, Liu Y, Liu X, Zheng J, Xue H . Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis. Am J Trop Med Hyg. 2020; 103(1):69-72. PMC: 7356425. DOI: 10.4269/ajtmh.20-0375. View

Jo Y, Choi S, Lee J, Park Y, Lee C, Yim J . Effect of Preadmission Metformin Use on Clinical Outcome of Acute Respiratory Distress Syndrome among Critically Ill Patients with Diabetes. Tuberc Respir Dis (Seoul). 2017; 80(3):296-303. PMC: 5526958. DOI: 10.4046/trd.2017.80.3.296. View

Jian M, Alexeyev M, Wolkowicz P, Zmijewski J, Creighton J . Metformin-stimulated AMPK-α1 promotes microvascular repair in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2013; 305(11):L844-55. PMC: 3882528. DOI: 10.1152/ajplung.00173.2013. View

10.

Ji M, Chen M, Hong X, Chen T, Zhang N . The effect of diabetes on the risk and mortality of acute lung injury/acute respiratory distress syndrome: A meta-analysis. Medicine (Baltimore). 2019; 98(13):e15095. PMC: 6456090. DOI: 10.1097/MD.0000000000015095. View

11.

Ramchand J, Patel S, Srivastava P, Farouque O, Burrell L . Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One. 2018; 13(6):e0198144. PMC: 5999069. DOI: 10.1371/journal.pone.0198144. View

12.

Zhang J, Dong J, Martin M, He M, Gongol B, Marin T . AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension. Am J Respir Crit Care Med. 2018; 198(4):509-520. PMC: 6118028. DOI: 10.1164/rccm.201712-2570OC. View

13.

Yu S, Christiani D, Thompson B, Bajwa E, Gong M . Role of diabetes in the development of acute respiratory distress syndrome. Crit Care Med. 2013; 41(12):2720-32. PMC: 4007199. DOI: 10.1097/CCM.0b013e318298a2eb. View

14.

Soberanes S, Misharin A, Jairaman A, Morales-Nebreda L, McQuattie-Pimentel A, Cho T . Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis. Cell Metab. 2018; 29(2):335-347.e5. PMC: 6365216. DOI: 10.1016/j.cmet.2018.09.019. View

15.

Ferrario C, Jessup J, Chappell M, Averill D, Brosnihan K, Tallant E . Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111(20):2605-10. DOI: 10.1161/CIRCULATIONAHA.104.510461. View

16.

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B . A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005; 11(8):875-9. PMC: 7095783. DOI: 10.1038/nm1267. View

17.

Chen A, Coura-Filho G, Rehder M . Clinical Characteristics of Covid-19 in China. N Engl J Med. 2020; 382(19):1860. DOI: 10.1056/NEJMc2005203. View

18.

Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer R, Stahl M . Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020; 181(4):905-913.e7. PMC: 7181998. DOI: 10.1016/j.cell.2020.04.004. View

19.

Bergmark B, Bhatt D, McGuire D, Cahn A, Mosenzon O, Steg P . Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. Circulation. 2019; 140(12):1004-1014. DOI: 10.1161/CIRCULATIONAHA.119.040144. View

20.

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S . Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581(7807):215-220. DOI: 10.1038/s41586-020-2180-5. View